DRAVP ID  DRAVPe00445

Peptide Name   IPB03(SARS-CoV-2-S (1172-1205))

Sequence  INASVVNIQKEIDRLNEVAKNLNESLIDLQELGK

Sequence Length  34

UniProt ID  P59594  P0DTC2 

Source  Synthetic construct(derived from SARS-CoV-2 S protein)

Target Organism  SARS-CoV-2,SARS-CoV,VSV

Assay  cell fusion assay, single-cycle infection assay

Activity 

• [Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.015 ± 0.002 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.947 ± 0.179 µM);
• SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=1.315 ± 0.463 µM);
• Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM).

Hemolytic Activity  No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity  No cytotoxicity information found in the reference(s) presented

Binding Target  membrane

Mechanism  The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can also inhibit the SARS-CoV pseudovirus efficiently.

PDB ID  None

Predicted Structure Download  DRAVPe00445

Linear/Cyclic  Linear

N-terminal Modification  Free

C-terminal Modification  Chol

Other Modification  None

Stereochemistry  L

Literature 1

Title   Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.

Pubmed ID   32376627

Reference   J Virol. 2020 Jul 1;94(14):e00635-20.

Author   Zhu Y, Yu D, Yan H, Chong H, He Y.

DOI   10.1128/JVI.00635-20